Your email has been successfully added to our mailing list.

×
0 0.000274119391454985 -0.000461018976537878 0.000585867899373235 0.00731400376291165 0.00993059795407243 0.00993059795407243 0.00993059795407243
Stock impact report

Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek [Yahoo! Finance]

Vertex Pharmaceuticals Incorporated (VRTX) 
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Company Research Source: Yahoo! Finance
vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be marketed under the brand name Alyftrek. Post the FDA's approval, the orally administered Alyftrek has been approved for use in CF patients aged six years and older who have at least one F508del mutation or another responsive mutation in the CF transmembrane conductance regulator (CFTR) gene responsive to the drug. The drug will be available at a wholesale acquisition cost of $370,269 on an annual basis. The FDA's decision came earlier than the expected PDUFA date of Jan 2, 2025. The approval is based on data from a comprehensive late-stage program, which showed that treatment with once-daily Alyftrek enhanced patient benefit compared to Vertex's blockbuster CF drug Trikafta (Kaftrio in Europe), which is required to be administered twice daily. The drug is also eligible for use in CF patients who have discontinued Trikafta or Vertex's other CF medicines. Similar regulatory Show less Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
VRTX alerts

from News Quantified
Opt-in for
VRTX alerts

from News Quantified